Examining the costs of single-and multilevel anterior cervical discectomy and fusion (ACDF) is important for the identification of cost drivers and potentially reducing patient costs. A novel tool at our institution provides direct costs for the identification of potential drivers. OBJECTIVE: To assess perioperative healthcare costs for patients undergoing an ACDF. METHODS: Patients who underwent an elective ACDF between July 2011 and January 2017 were identified retrospectively. Factors adding to total cost were placed into subcategories to identify the most significant contributors, and potential drivers of total cost were evaluated using a multivariable linear regression model. RESULTS: A total of 465 patients (mean, age 53 ± 12 yr, 54% male) met the inclusion criteria for this study. The distribution of total cost was broken down into supplies/implants (39%), facility utilization (37%), physician fees (14%), pharmacy (7%), imaging (2%), and laboratory studies (1%). A multivariable linear regression analysis showed that total cost was significantly affected by the number of levels operated on, operating room time, and length of stay. Costs also showed a narrow distribution with few outliers and did not vary significantly over time. CONCLUSION: These results suggest that facility utilization and supplies/implants are the predominant cost contributors, accounting for 76% of the total cost of ACDF procedures. Efforts at lowering costs within these categories should make the most impact on providing more cost-effective care.
B
ecause of the projected increases in overall healthcare cost and changes in reimbursement pathways, significant emphasis has been placed within hospital systems on reducing healthcare costs while maintaining quality of care. Within neurosurgical practice, several recent studies have discussed efforts to understand and control costs. 1, 2 To identify cost drivers that have the most influence on healthcare costs, the Value-Driven Outcomes (VDO) tool was developed to provide meaningful data based
ABBREVIATIONS:
ACDF, anterior cervical discectomy and fusion; ASA, American Society of Anesthesiologists; CPT, common procedural terminology; OR, operating room; VDO, valuedriven outcome on the direct costs, not charges, of various patient encounters. 3, 4 By providing the ability to evaluate costs directly, the VDO system can be used to analyze the cost-effectiveness of specific treatments within neurosurgical care at an individual surgeon level. 4 A common neurosurgical procedure in the treatment of cervical spondylosis is the anterior cervical discectomy and fusion (ACDF). 5, 6 The purpose of this study was to evaluate the potential cost drivers in ACDF surgery within neurosurgical care by using the VDO database to identify targets for reducing cost.
METHODS
This study was approved by the Institutional Review Board with a waiver of consent prior to data collection. Patients who underwent a single-, 2-, or 3-level ACDF between July 2011 and January 2017 were identified via retrospective chart review using the electronic health record and the VDO tool. The VDO tool is unique in the medical literature in that it calculates the direct costs to patient care and is not based on charges or revenues as seen in most prior cost-effectiveness studies. These costs are amounts required to purchase hardware, pay for facility fees and salaries, and purchase medications for patient administration. Hospital charges are then a variable percentage above these costs.
Patients were included based on the common procedural terminology (CPT) codes for anterior instrumentation procedures in the spine 22845 (2-3 vertebral segments) and 22846 (4-7 vertebral segments). Patients were excluded if the procedure was performed because of infection, trauma, 2-stage surgery, neoplasia, or revision surgery. All surgical cases were performed using anterior plate fixation and interbody fusion by one of 10 neurosurgeons at our institution. While all providers at our institution utilize an interbody graft and plate fixation, the specific surgical techniques used during surgery, such as grafts, neuromonitoring, and postoperative imaging, differed among providers. A manual chart review was performed for all cases in order to assure that a 1-, 2-, or 3-level ACDF was performed.
The demographic data collected included age and sex. Health status prior to surgical intervention was collected using the American Society of Anesthesiologists (ASA) physical status system. The surgical data collected included the number of levels operated on (1, 2, or 3), operating room (OR) time, and the identity of the surgeon performing the operation. The postoperative data included hospital course, complications, length of stay, and discharge disposition. Length of stay was calculated by the number of whole days between discharge date and admission date. Complications were assessed based on the patient discharge summary and divided into minor complications, which required observation or medication, and major complications, which required repeat surgery or admission to a critical care unit. Using the VDO database, direct costs collected included those for facility utilization, pharmacy, supplies and implants, imaging, and laboratory studies for each patient. Individual surgeon fees were gathered based on the 2017 Medicare reimbursement for CPT codes 22845 and 22846.
Actual dollar amounts are not presented in the data set but are shown as a percentage of the total cost for each ACDF procedure in this cohort. This converts each patient's total cost to a % that the particular patient contributes to the cost of the cohort, thus allowing comparison of subtotal costs and costs between patients without disclosing proprietary dollar amounts. Means and standard deviations were calculated for each variable based on procedure type. An adjusted multivariable linear regression model was constructed for variables potentially affecting total cost. All statistical analysis was performed on SPSS (V24.0, IBM Corporation, Armonk, New York), and P < .05 was considered statistically significant. 
RESULTS
A total of 465 patients met the inclusion criteria for this study. Within the cohort, 227 patients underwent a single-level ACDF, 179 underwent a 2-level ACDF, and 59 underwent a 3-level ACDF (Table 1) . The study population was 54% male, with a mean age of 53 ± 12 yr. The ASA grades were healthy in 39 (8.4%) patients, mild systemic disease in 309 (66.5%), severe systemic disease in 109 (23.4%), and incapacitating systemic disease in 8 (1.7%). The median length of stay was 1 d (Figure A) . At the point of discharge, 416 (89.5%) patients were discharged to home or self-care, 14 (3.0%) to home with healthcare services, 13 (2.8%) to an acute rehabilitation facility, 20 (4.3%) to law enforcement, and 2 (0.4%) to a skilled nursing facility ( Figure B) .
The overall complication rate was 3.2%, with a total of 15 complications occurring in the 465 procedures ( Table 2 ). The overall minor complication rate was 1.5%; minor complications involved dysphagia (n = 3), minor infection (n = 2; (C. difficile; community-acquired pneumonia), hematoma without evacuation (n = 1), and atrial flutter (n = 1). The overall major complication rate was 1.7%; major complications included severe dysphagia requiring a feeding tube (n = 1), hardware failure requiring reoperation (n = 3), hematoma with evacuation (n = 3), and respiratory depression secondary to medication (n = 1).
The distribution of total cost was represented by supplies and implants (39%), facility utilization (37%), physician fees (14%), pharmacy (7%), imaging (2%), and laboratory studies (1%), each defined as a percentage of total cost ( Figure C) . A breakdown for each of these subcategory costs is presented based on the extent of the procedure (number of levels; Table 3 ). Supplies and implants included all intraoperative and postoperative surgical supplies, but most of this cost was related to the spine instrumentation. A significant difference in facility (P = .01) and total (P = .02) cost was seen between patients with and without complications ( Figure D) . Costs in Figure D are reported as a mean % of total so the groups can be compared without disclosing cost dollars as per institutional agreement.
An adjusted multivariable linear regression was performed to assess potential cost drivers such as age, sex, ASA grade, number of levels operated on, OR minutes, complications, length of stay, and discharge disposition ( Table 4 ). The standardized β coefficient and P-value denote whether a potential cost driver may act as a significant predictor of total cost. In our linear regression model, the number of levels operated on (β = 0.327, P < .001), OR minutes (β = 0.287, P < .001), and length of stay (β = 0.457, P < .001) were significant factors in driving the total cost of an ACDF. A multivariable regression where OR minutes was excluded continued to show that the number of operated levels and length of stay were significant cost drivers. In other words, having more levels operated on, being in the OR for a longer time, and requiring a longer stay increased the total cost of ACDF in this cohort. Increased length of stay is the most significant cost driver in the data set compared with all other variables evaluated.
There was a significant relationship among length of stay, number of levels operated on, and the combined total cost of the cohort ( Figure E) . Cost differences between different surgeons were negligible for various levels of fusion ( Figure F) . As in Figure D described above, costs reported as percentages in Figure E and F allow comparability without disclosing cost amounts.
DISCUSSION A Novel Tool for Evaluating Cost-Effective Care
The VDO database was developed to facilitate data-driven improvements and cost containment in health care. 3, 4 With transparency in direct costs by patient condition, the database has led to lower costs and better quality at this institution. 7 Three clinical projects have already seen a reduction in costs and improved quality of care since the implementation of the VDO. 4 ACDF is one of the most commonly performed surgeries in the treatment of cervical spondylosis because of its durability and cost-effectiveness. 5, [8] [9] [10] Consequently, we utilized the VDO system to examine ACDF cost drivers as a model for VDOs within neurosurgical spine care. The major components of total cost in this study were facility utilization and supplies/implants, which together comprise 76% of the total costs of ACDFs. Not surprisingly, the number of levels operated on, operating room time, and length of stay significantly increased the cost of surgery. 
Cost-Effectiveness Research with ACDF Procedures
Advances may be made towards reducing costs while maintaining quality of care with ACDF procedures. Among all the variables analyzed, the strongest predictor of total cost at this institution was length of stay; the median length of stay was 1 d, and 89.5% of patients were discharged to home or self-care. This finding supports one evidence-based idea to reduce costs by reducing facility utilization and length of stay by increasing the number of outpatient spinal operations for appropriate candidates. [11] [12] [13] [14] The initial concerns about patient safety, rate of complications, and morbidity/mortality when performing an ACDF in the outpatient setting have slowed its implementation; 15 however, multiple studies have suggested that ACDF procedures can be performed in an outpatient setting as a costsaving measure without compromising patient safety. 5, 8, 11, 12, 15 In a study of 1000 patients at Vanderbilt University Hospital, researchers concluded that single-and 2-level ACDFs could be performed successfully in the outpatient setting with a low complication rate. 15 In another study, researchers concluded that ACDFs done in outpatient surgical centers have comparable morbidity, readmission rates, and lower costs compared with ACDFs performed in inpatient settings. 12 Furthermore, in a nationwide analysis representing more than 250 hospitals and 7288 patients, researchers observed that ambulatory surgical centers were a safe and cost-effective alternative for single-and 2-level ACDFs. 5 Based on these studies and our results showing a significant impact of length of stay on overall cost, carefully selecting patients for outpatient surgery may reduce facility utilization and total costs for ACDFs. Interestingly in our series, complication was not a significant driver of cost. This could have been due to the rarity of the event or potentially low cost increases for complications after ACDF.
Supply and implant costs were another significant contributor to total cost in our cohort. To help mitigate such costs, studies suggest that simply making physicians more aware of supply and implant costs can decrease this component of care costs. [16] [17] [18] [19] [20] [21] [22] [23] Surgeons may not have an accurate knowledge base for the costs of supplies and implants. 20, 24 The results of a prospective study on cost education for surgeons to determine a more efficient use of explanted instrumentation during single-level ACDFs showed decreased costs for screws, plates, and allograft spacers after education. 21 In a follow-up study, the researchers performed a quarterly spine surgeon education program where data on costs and reasons for operative waste were posted over the neurosurgery and orthopedic scrub sinks. The investigators saw a significant reduction in orthopedic operative wastes by 64.7% and 61% and in neurosurgery operative wastes by 49.4% and 45.2% in years 1 and 2, respectively. 22 If applied to ACDF procedures, our findings suggest that these strategies may have a significant impact on decreasing surgical costs. Another approach could potentially involve systematic, evidence-based comparisons of different implants or the combination of the VDO data with an outcomes database in order to encourage cost streamlining. Strategies used at our institution to influence these variables have included streamlined preoperative work-ups, an interdisciplinary spine indications conference to improve uniformity of procedure selection, and policies to standardize implant costs across different vendors. Such a process for the review of new implants may also be helpful in controlling cost. Lastly, the impact of financial relationships between surgeons and manufacturing companies as well as improved transparency in the cost control may play a role in reducing implant cost.
Limitations
A limitation of this study is the nature of performing research at a single-center site. The strategies suggested in this ACDF study for cost-effective care must be considered in the context of changing surgical practices, varying individual provider approaches, and identifying other cost driving factors in spine care at individual institutions. In addition, the retrospective nature of clinical variables and cost collection may bias the accuracy of these variables. Follow-up outpatient costs or out-of-pocket patient costs would not be captured by these data. Further prospective analysis would be necessary to confirm the study findings. The physician professional fees were also estimated based on CPT codes 22845 and 22846 because we were unable to obtain the direct physician reimbursement amounts. As a result, total professional fee costs may not capture the complexity and variability of billing reimbursement for ACDFs. Another limitation of this study is the inability to report proprietary dollar costs, which limits comparability of this study's findings with other reported cost-effectiveness analyses.
CONCLUSION
This study demonstrates that facility utilization and supplies and implants are the most significant cost contributors for ACDF procedures, comprising 76% of the overall costs, and the most significant cost driver for ACDF procedures was length of stay. Directing attention at lowering costs within these categories, such as performing outpatient operations and supply/implant cost education, has the potential to make an impact on providing more cost-effective care.
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